5 août 2022 – The European Medicines Agency (EMA) published the assessment report for Nuvaxovid supporting its extension of indication to include adolescents aged 12 to 17. Nuvaxovid is a vaccine for preventing Covid-19 in people aged 12 years and older.

For more information, see here.